IPCA Laboratories LimitedPharmaceuticals & HealthcareIPCALAB
Q1 FY27 earnings callIPCA Laboratories Limited
Ipca delivered robust 21% revenue growth and significantly improved EBITDA margins by 4.49 percentage points to 22.88%, revising its full-year revenue growth guidance upward.
Numbers
| Metric | This quarter | Change | Five-quarter trend |
|---|---|---|---|
| Consolidated Revenue | INR 2,788 crores | 21% | |
| Consolidated EBITDA Margin | 22.88% | 4.49% | |
| India Domestic Formulations Revenue | INR 1,082 crores | 13% | |
| India Chronic Segment Growth | 17.2% | — | |
| Overall Export Revenue | INR 603 crores | 34% | |
| API Business Revenue | INR 424 crores | 30% | |
| Net Debt | INR 193 crores | — |
Financials
| Quarter | Revenue | Net profit (PAT) | Basic EPS |
|---|---|---|---|
| Q3 FY25 | ₹2,245.37 Cr+9.4% YoY-4.7% QoQ | ₹276.36 Cr+25% YoY+12.5% QoQ | ₹9.78+37.9% YoY+8.1% QoQ |
| Q2 FY25 | ₹2,354.90 Cr+15.8% YoY+12.5% QoQ | ₹245.75 Cr+80% YoY+23.4% QoQ | ₹9.05+58.2% YoY+19.4% QoQ |
| Q1 FY25 | ₹2,092.63 Cr+31.8% YoY+2.9% QoQ | ₹199.14 Cr+21.4% YoY+14872.9% QoQ | ₹7.58+18.1% YoY+222.6% QoQ |
| Q4 FY24 | ₹2,033.01 Cr+34.5% YoY-1% QoQ | ₹1.33 Cr-98.3% YoY-99.4% QoQ | ₹2.35-22.2% YoY-66.9% QoQ |
| Q3 FY24 | ₹2,052.86 Cr+32.8% YoY+0.9% QoQ | ₹221.00 Cr+101.4% YoY+61.9% QoQ | ₹7.09+66.8% YoY+24% QoQ |
TL;DR
- Consolidated revenue grew 21% to INR 2,788 Cr, with all business segments performing well.
- Consolidated EBITDA margin improved sharply to 22.88%, up 4.49 percentage points YoY, leading to a 50% increase in absolute EBITDA.
- Domestic formulations grew 13%, with chronic segment outperforming the market at 17.2% growth.
- Overall export business grew 34%, driven by a 27% growth in the generic business excluding tenders and a 107% surge in institutional generic business (partly due to delayed shipments).
- Management revised its FY27 revenue growth guidance upward to 14-16% from 12-13% and EBITDA margin guidance to 23% from 22%.
- The company plans a CapEx of INR 700-800 Cr this year for capacity expansion and biotech R&D, while maintaining a net cash positive position.
Said on the call
“Overall, despite all these factors, we could deliver better profitability.”
From the Q&A
| Topic | What management said |
|---|---|
| India Business Performance | Management clarified that both chronic (17.2%) and acute (8.9%) segments outperformed the market, with the acute performance dampened by a 24% decline in the antimalarial segment. |
| Guidance Revision | Full-year revenue growth guidance was upgraded to 14-16% from 12-13%, driven by better performance in generic business, India, and API. Consolidated EBITDA margin guidance was revised up to 23% from 22%. |
| U.S. Business and Launches | Ipca and Unichem combined are expected to launch 7-8 products annually in the U.S. Management expects consistent growth of 15-17% for the U.S. business over the next few years. |
| Cost and Margin Outlook | Despite significant increases in material and logistics costs, management does not foresee margin pressure going forward, citing operational leverage and cost control. |
| Capital Allocation and Biotech | Planned CapEx for the year is INR 700-800 Cr, focused on capacity expansion and biotech. The company has 7 biosimilar candidates, with 2 in advanced stages, targeting global markets and potential launches around FY30. |
| Financial Position | The company has minimal debt (INR 193 Cr) and expects interest cost to decline further, positioning it as net cash positive. |
Guidance
- Revised FY27 revenue growth guidance: 14% to 16% (up from 12-13%).
- Revised FY27 consolidated EBITDA margin guidance: 23% (up from 22%).
- Institutional generic business expected to be around INR 260 Cr to INR 300 Cr for the full year.
- Capital expenditure for the current year: INR 700 Cr to INR 800 Cr.
- Long-term EBITDA margin target for Ipca standalone: around 30%. Long-term consolidated target: 25-26%.
Source
Summary written from the transcript filed by IPCA Laboratories Limited for the call held on 14 Aug 2026; published 22 Aug 2026, 13:10 IST.